Moderna says norovirus vaccine trial on FDA clinical hold
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Moderna posts bigger loss than expected as it scales down manufacturing
Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to ...
Moderna Posts Bigger Loss Than Expected as Vaccine Maker Scales Down Manufacturing
Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...
Moderna’s Results Reaffirm a Grim Picture for Vaccine Maker
The vaccine maker Moderna had no Valentine’s Day chocolates for investors when its fourth-quarter financial results came out ...
Moderna Q4 Earnings Preview: COVID-19 Vaccine Sales, Bird Flu Vaccine Candidates On Watch
Moderna is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to expect in ...
2MRNA : Moderna Struggles With Declining Q4 COVID Vaccine Sales, Stock Slides
Moderna reported a Q4 EPS loss of $2.91, missing estimates, with revenue down 66% YoY to $966 million. The company reaffirmed ...
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 ...
Moderna Posts Wider-Than-Expected Q4 Loss, 2025 Sales Guide Disappoints
Moderna reported a wider loss than expected for the fourth quarter on Friday morning, and the drugmaker's sales forecast for ...
Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
Investor's Business Daily on MSN25m
Moderna Stock Reverses As CEO Stephane Bancel Deflects Concerns Over RFK Jr.
Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.
HSBC to unveil $1.5 billion of annual cost savings on February 19, FT reports
HSBC is preparing to report $1.5 billion of annual cost savings from the changes implemented under its broad restructuring ...
pharmaphorum21h
Blow to Moderna as EU nixes mRNA vaccine patent
The European Patent Office has said it has invalidated a patent held by Moderna on mRNA-based COVID-19 vaccines, the latest development in an increasingly acrimonious dispute between the company ...